Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Biogen Inc.NASDAQ: BIIB

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $495.6M fell 6.5% year over year, ahead of the -19.9% change in trailing-twelve-month research & development. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.

Context

  • Research & development amounted to 19.9% of revenue in FY2025, down 5.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -6.5% holds above the trailing-twelve-month pace of -19.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$495.6M-13.5% QoQ
Last fiscal yearDec 2025
$1.95B-21.5% YoY
LTMJun 2026
$1.95B-19.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.5%——
1 year-21.5%——
3-year CAGR-9.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
1.95B USD
Year-over-year change
-21.5%
4-year CAGR
-12.9%

Research & Development vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's LTM Jun 2026 research & development of $1.95B is the 7th highest of the 11 companies compared; the peer median is $5.36B.
  • Its year-over-year change of -19.9% is the lowest of 11, against a peer median of +6.8%.
  • Research & development amounts to 19.6% of revenue for BIIB, versus a peer median of 27.8%.
BIIB Competitors Peer median
Research & Development for BIIB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$15.01B -0.3%+13.4%24.1%
LLYEli Lilly and CompanyLTM Jun 2026$14.6B +23.4%+22.9%18.3%
PFEPfizer Inc.LTM Jun 2026$11.05B +7.0%-3.0%17.3%
AMGNAmgen Inc.LTM Jun 2026$7.64B +19.3%+16.3%20.0%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$6.46B +16.9%+24.2%41.6%
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 2026$4.25B +6.5%+12.2%32.7%
BIIBBiogen Inc.LTM Jun 2026$1.95B -19.9%-9.0%19.6%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.51B +30.1%+14.5%31.4%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$923.16M +4.7%+3.2%96.2%
UTHRUnited Therapeutics CorporationLTM Jun 2026$551.5M +6.0%+19.4%17.5%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$433.31M -14.7%-11.3%43.0%
Peer median (excluding BIIB) $5.36B+6.8%+13.9%27.8%

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.98B10.17B9.84B9.68B9.81B
Cost of Revenue2.11B2.28B2.53B2.31B2.9B
Gross Profit8.87B7.9B7.3B7.37B6.91B
Gross Margin80.8%77.6%74.2%76.1%70.5%
Research & Development3.4B2.6B2.7B2.49B1.95B
Selling, General & Admin2.68B2.41B2.5B2.39B2.43B
Operating Expenses6.08B5.01B5.2B4.88B5.04B
Depreciation & Amortization487.7M518.4M494.8M673.2M779.9M
EBITDA3.92B3.54B2.38B3B2.95B
EBITDA Margin35.7%34.8%24.2%31.0%30.0%
Operating Income2.79B2.89B2.1B2.49B1.88B
Operating Margin25.4%28.4%21.3%25.7%19.1%
Interest Income11M89.3M276.5M67.6M87.8M
Interest Expense253.6M246.6M246.9M250.3M246M
Other Income / Expenses(1.01B)705.3M(800.5M)(584.3M)(476M)
Income Before Tax1.78B3.59B1.3B1.91B1.4B
Pre-Tax Margin16.2%35.3%13.2%19.7%14.3%
Income Tax Expense52.5M632.8M135.3M273.8M108.11M
Net Income1.56B3.05B1.16B1.63B1.29B
Net Margin14.2%29.9%11.8%16.9%13.2%
EPS (Basic)10.4420.978.0211.208.85
EPS (Diluted)10.4020.877.9711.198.83
Weighted Avg Shares149.1M145.3M144.7M145.7M146.7M
Weighted Avg Shares (Diluted)149.6M146M145.6M145.9M146.7M

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.